Antihypertensive therapy and cerebrovascular protection

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: Stroke represents the most devastating cardiovascular disease in the Western world, accounting for approximately 700 000 cases each year, including 500 000 first attacks and 200 000 recurrent episodes. High blood pressure is the most relevant modifiable risk factor for developing stroke. RECENT FINDINGS: In hypertensive patients, especially those with additional cardiovascular risk factors or clinical settings such as diabetes, target organ damage or associated clinical conditions, even small decreases in blood pressure levels are associated with large reductions in the incidence of cerebrovascular events. The benefits of blood pressure reductions, however, are not strictly proportional to stroke incidence, and it has been recently postulated that the different classes of antihypertensive drugs may have specific properties for organ protection and cerebrovascular accident prevention. SUMMARY: In particular, the hypothesis of a higher cerebrovascular protection provided by newer antihypertensive agents with respect to the conventional antihypertensive therapy is an attractive perspective that deserves further investigation.

Original languageEnglish
Pages (from-to)498-504
Number of pages7
JournalCurrent Opinion in Nephrology and Hypertension
Volume15
Issue number5
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Antihypertensive Agents
Stroke
Accident Prevention
Blood Pressure
Western World
Incidence
Therapeutics
Cardiovascular Diseases
Hypertension

Keywords

  • Angiotensin II receptor blockers
  • Antihypertensive therapy
  • Calcium-channel blockers
  • Cerebrovascular disease
  • Hypertension
  • Stroke

ASJC Scopus subject areas

  • Nephrology
  • Internal Medicine

Cite this

Antihypertensive therapy and cerebrovascular protection. / Volpe, Massimo; Tocci, Giuliano.

In: Current Opinion in Nephrology and Hypertension, Vol. 15, No. 5, 09.2006, p. 498-504.

Research output: Contribution to journalArticle

@article{3e67e3a4ac604ed6ba7507ab693ec19e,
title = "Antihypertensive therapy and cerebrovascular protection",
abstract = "PURPOSE OF REVIEW: Stroke represents the most devastating cardiovascular disease in the Western world, accounting for approximately 700 000 cases each year, including 500 000 first attacks and 200 000 recurrent episodes. High blood pressure is the most relevant modifiable risk factor for developing stroke. RECENT FINDINGS: In hypertensive patients, especially those with additional cardiovascular risk factors or clinical settings such as diabetes, target organ damage or associated clinical conditions, even small decreases in blood pressure levels are associated with large reductions in the incidence of cerebrovascular events. The benefits of blood pressure reductions, however, are not strictly proportional to stroke incidence, and it has been recently postulated that the different classes of antihypertensive drugs may have specific properties for organ protection and cerebrovascular accident prevention. SUMMARY: In particular, the hypothesis of a higher cerebrovascular protection provided by newer antihypertensive agents with respect to the conventional antihypertensive therapy is an attractive perspective that deserves further investigation.",
keywords = "Angiotensin II receptor blockers, Antihypertensive therapy, Calcium-channel blockers, Cerebrovascular disease, Hypertension, Stroke",
author = "Massimo Volpe and Giuliano Tocci",
year = "2006",
month = "9",
doi = "10.1097/01.mnh.0000242175.59823.f2",
language = "English",
volume = "15",
pages = "498--504",
journal = "Current Opinion in Nephrology and Hypertension",
issn = "1062-4821",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Antihypertensive therapy and cerebrovascular protection

AU - Volpe, Massimo

AU - Tocci, Giuliano

PY - 2006/9

Y1 - 2006/9

N2 - PURPOSE OF REVIEW: Stroke represents the most devastating cardiovascular disease in the Western world, accounting for approximately 700 000 cases each year, including 500 000 first attacks and 200 000 recurrent episodes. High blood pressure is the most relevant modifiable risk factor for developing stroke. RECENT FINDINGS: In hypertensive patients, especially those with additional cardiovascular risk factors or clinical settings such as diabetes, target organ damage or associated clinical conditions, even small decreases in blood pressure levels are associated with large reductions in the incidence of cerebrovascular events. The benefits of blood pressure reductions, however, are not strictly proportional to stroke incidence, and it has been recently postulated that the different classes of antihypertensive drugs may have specific properties for organ protection and cerebrovascular accident prevention. SUMMARY: In particular, the hypothesis of a higher cerebrovascular protection provided by newer antihypertensive agents with respect to the conventional antihypertensive therapy is an attractive perspective that deserves further investigation.

AB - PURPOSE OF REVIEW: Stroke represents the most devastating cardiovascular disease in the Western world, accounting for approximately 700 000 cases each year, including 500 000 first attacks and 200 000 recurrent episodes. High blood pressure is the most relevant modifiable risk factor for developing stroke. RECENT FINDINGS: In hypertensive patients, especially those with additional cardiovascular risk factors or clinical settings such as diabetes, target organ damage or associated clinical conditions, even small decreases in blood pressure levels are associated with large reductions in the incidence of cerebrovascular events. The benefits of blood pressure reductions, however, are not strictly proportional to stroke incidence, and it has been recently postulated that the different classes of antihypertensive drugs may have specific properties for organ protection and cerebrovascular accident prevention. SUMMARY: In particular, the hypothesis of a higher cerebrovascular protection provided by newer antihypertensive agents with respect to the conventional antihypertensive therapy is an attractive perspective that deserves further investigation.

KW - Angiotensin II receptor blockers

KW - Antihypertensive therapy

KW - Calcium-channel blockers

KW - Cerebrovascular disease

KW - Hypertension

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=33747389709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747389709&partnerID=8YFLogxK

U2 - 10.1097/01.mnh.0000242175.59823.f2

DO - 10.1097/01.mnh.0000242175.59823.f2

M3 - Article

C2 - 16914962

AN - SCOPUS:33747389709

VL - 15

SP - 498

EP - 504

JO - Current Opinion in Nephrology and Hypertension

JF - Current Opinion in Nephrology and Hypertension

SN - 1062-4821

IS - 5

ER -